The products treat diseases such as depression, anxiety, psychosis, alcohol dependence, myasthenia gravis and Parkinson disease.
European central nervous system (CNS) specialist Neuraxpharm, with 35 years of experience in CNS disorders, has agreed to buy two portfolios from pharma giant Sanofi. The purchase includes 17 molecules that represent 38 brands marketed in over 50 countries.
The products treat diseases such as depression, anxiety, psychosis, alcohol dependence, myasthenia gravis and Parkinson disease. The CNS portfolio includes Nozinan, Tranxene, Tiapridal, Dogmatil, and Largactil. The pain and vascular portfolio includes Topalgic and Trental.
"There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven by an ageing population and an increasing awareness of mental health. This phenomenon is a global trend," Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, said in a prepared statement. "With the upcoming acquisition, we will not only strengthen our presence in Europe, but also lay the ground for further expanding our international presence."
The acquisition enables Neuraxpharm to bolster its position as a leading European specialty pharmaceutical company focused on CNS, and aligns with Sanofi CEO Paul Hudson’s streamlined product strategy launched in 2019. Sanofi calls the strategy a "play to win," which means divesting underperforming areas and focusing purposely on high performing products.
Following the acquisition, Neuraxpharm's annual gross sales could be around $600 million.
Robin Robinson is a contributing writer for HealthLeaders.
KEY TAKEAWAYS
Acquisition bolsters Neuraxpharm's position as a leading European CNS specialty pharmaceutical company.
Allows Sanofi to focus on its most promising medicines.
Following the acquisition, Neuraxpharm's annual gross sales could be around $600 million.